Anti-GPVI antibody [EPR8347]
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(5 Publications)
Rabbit Recombinant Monoclonal GPVI antibody. Suitable for WB and reacts with Human samples. Cited in 5 publications.
View Alternative Names
Platelet glycoprotein VI, GPVI, Glycoprotein 6, GP6
- WB
Unknown
Western blot - Anti-GPVI antibody [EPR8347] (AB129019)
All lanes:
Western blot - Anti-GPVI antibody [EPR8347] (ab129019) at 1/10000 dilution
All lanes:
Human platelet lysate at 10 µg
Secondary
All lanes:
HRP-conjugated goat anti-rabbit at 1/2000 dilution
Predicted band size: 37 kDa
false
Related conjugates and formulations (1)
-
Anti-GPVI antibody [EPR8347] - BSA and Azide free
Reactivity data
Product details
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The target participates in the formation of platelet activation complexes. GPVI partners with the Fc receptor γ-chain to transmit activation signals upon collagen binding. This process results in platelet shape change granule secretion and aggregation which are all critical steps for clot formation. By interacting with collagen GPVI ensures that platelets can effectively respond to vascular damage particularly in arterial vessels where high shear forces prevail.
Pathways
The glycoprotein VI contributes significantly to the immune and coagulation pathways. It activates the enzyme Syk kinase following collagen binding which further triggers the downstream signaling pathways like the MAPK pathway leading to platelet activation. GPVI works closely with other receptors like integrin α2β1 and the glycoprotein Ib/V/IX complex reinforcing platelet-collagen interactions and stabilizing the platelet plug formation during thrombus growth.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (5)
Recent publications for all applications. Explore the full list and refine your search
Haematologica 110:2792-2798 PubMed40468949
2025
Applications
Unspecified application
Species
Unspecified reactive species
Drug delivery and translational research 15:3098-3118 PubMed39873880
2025
Applications
Unspecified application
Species
Unspecified reactive species
Aging 12:12002-12018 PubMed32570219
2020
Applications
Unspecified application
Species
Unspecified reactive species
Platelets 31:33-42 PubMed30721642
2019
Applications
Unspecified application
Species
Unspecified reactive species
Alzheimer's & dementia : the journal of the Alzhei 14:1438-1449 PubMed29792870
2018
Applications
WB
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com